BioSpace News Archive

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer Joseph Moscato, and his management team Friday, November 29, 2019 at 9:30 AM Eastern time:

PAR, Inc. announced recently it has invested in local start-up Immertec, a company that applies virtual reality technology to medical and surgical training.

The forest industry is a key economic sector in British Columbia (BC), providing 32% ($14.1 billion) of B.C.’s total exports and close to $1 billion in revenue to the provincial government in 2017.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing innovative immunotherapies, and HalioDx, the immuno-oncology diagnostic company, today announced a collaboration to conduct a translational investigation of immune biomarkers as part of the ongoing Phase 3 clinical trial of neoepitope combination Tedopi® in non-small cell lung cancer (NSCLC) patients.

Clinic had significant donor eligibility violations, including donor screening and testing

Access-Power, Inc. is in the final stages of a Corporate Action Request with a FINRA process whereby we earlier announced the merger with Grand Haven MM LLC.

Grant Will Support the Transfer of The Quilt, its Programs and a New Public Education Initiative to Reach Communities Adversely Impacted by HIV

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is scheduled to participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 1:00 PM ET at the Lotte New York Palace Hotel in New York City.

Generex Biotechnology Corporation (OTCQB: GNBT) today announced that due to the issues announced yesterday in a shareholder alert, and because of the resulting sharp decline of over 150% in our share price, the Company has decided to postpone the 1:1 dividend.

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in two investor conferences in December.